# Respiratory, Autonomic, Hematology & Oncology Pharmacology

> Asthma/COPD inhalers & biologics, autonomic agonists/antagonists, anticoagulants, antiplatelets, thrombolytics, immunosuppressants, and classic/targeted antineoplastics.

- **Canonical URL:** https://flashcards.world/flashcards/sets/27366501-2807-4867-a801-100d5c9b99a0/
- **Markdown URL:** https://flashcards.world/flashcards/sets/27366501-2807-4867-a801-100d5c9b99a0.md
- **Category:** Top 200 Prescribed Drugs (Brand, Generic, Class & MOA)
- **Level:** advanced
- **Languages:** en → en
- **Total Cards:** 32

## Flashcards (32 Cards)

| # | Front (Term / Prompt) | Back (Definition / Answer) | Example | Multiple-Choice Options |
| :--- | :--- | :--- | :--- | :--- |
| 1 | Omalizumab, Mepolizumab/Benralizumab & Dupilumab — Severe Eosinophilic/Allergic Asthma Biologics | Omalizumab: anti-IgE mAb (binds Fc region of free IgE). Mepolizumab: anti-IL-5 mAb; Benralizumab: anti-IL-5Ralpha mAb (depletes eosinophils). Dupilumab: anti-IL-4Ralpha mAb blocking both IL-4 and IL-13 signaling (treats severe eosinophilic asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps). |  |  |
| 2 | Unfractionated Heparin (UFH) vs Enoxaparin (LMWH) vs Fondaparinux — Mechanism, Monitoring & Renal Clearance | Activate antithrombin III: UFH catalyzes inactivation of both Factor IIa (thrombin) and Factor Xa (monitored via aPTT; safe in ESRD; completely reversed by protamine sulfate). Enoxaparin (LMWH) and Fondaparinux (synthetic pentasaccharide) preferentially inhibit Factor Xa (monitored via anti-Xa levels if needed; renally cleared—avoid or dose-reduce if CrCl < 30 mL/min). |  |  |
| 3 | Tacrolimus & Cyclosporine vs Mycophenolate Mofetil vs Sirolimus — Transplant Immunosuppressants | Tacrolimus (binds FKBP-12) and cyclosporine (binds cyclophilin) inhibit calcineurin -> prevent NFAT dephosphorylation and IL-2 transcription (both cause dose-limiting nephrotoxicity, hypertension, and neurotoxicity; tacrolimus causes post-transplant diabetes, cyclosporine causes gingival hyperplasia and hirsutism). Mycophenolate inhibits IMP dehydrogenase (blocks de novo purine synthesis in T/B cells; GI toxicity/cytopenias). Sirolimus binds FKBP-12 to inhibit mTOR (blocks IL-2 receptor signaling; non-nephrotoxic). |  |  |
| 4 | Filgrastim (G-CSF), Epoetin Alfa (EPO) & Romiplostim/Eltrombopag — Hematopoietic Growth Factors | Filgrastim/pegfilgrastim stimulate granulocyte proliferation to prevent febrile neutropenia (causes bone pain). Epoetin alfa/darbepoetin stimulate erythropoiesis in anemia of CKD (causes hypertension and thrombosis if Hb > 11 g/dL). Romiplostim and eltrombopag are thrombopoietin (TPO) receptor agonists used in refractory immune thrombocytopenia (ITP). |  |  |
| 5 | Apixaban & Rivaroxaban vs Dabigatran — DOAC Mechanisms & Specific Reversal Agents | Apixaban and rivaroxaban directly inhibit free and clot-bound Factor Xa (reversed by andexanet alfa or 4-factor PCC). Dabigatran is a direct oral thrombin (Factor IIa) inhibitor (reversed specifically by the monoclonal antibody fragment idarucizumab / Praxbind). |  |  |
| 6 | Rasburicase vs Allopurinol — Prevention and Management of Tumor Lysis Syndrome (TLS) | Aggressive lysis of high-turnover hematologic malignancies releases massive intracellular K+, PO4-, and nucleic acids (hyperuricemia, hypocalcemia, acute urate nephropathy). Allopurinol prevents NEW uric acid formation by inhibiting xanthine oxidase; Rasburicase is recombinant urate oxidase that directly oxidizes EXISTING uric acid into water-soluble allantoin (contraindicated in G6PD deficiency due to H2O2 production). |  |  |
| 7 | Ipratropium (SAMA) & Tiotropium/Umeclidinium (LAMA) — Mechanism & Role in COPD vs Asthma | Competitively block M3 muscarinic receptors on airway smooth muscle, preventing vagally mediated bronchoconstriction and mucus secretion. LAMAs are cornerstone maintenance therapy in COPD and severe asthma. Adverse effects: Dry mouth and acute urinary retention in men with BPH. |  |  |
| 8 | 5-Fluorouracil (5-FU) / Capecitabine & Cytarabine — Pyrimidine Antimetabolites | 5-FU (and oral prodrug capecitabine) forms 5-FdUMP, which complexes with leucovorin to inhibit thymidylate synthase, causing 'thymine-less death' in GI/breast cancers (causes myelosuppression and palmar-plantar erythrodysesthesia / hand-foot syndrome). Cytarabine (Ara-C) inhibits DNA polymerase in AML (causes pancytopenia and cerebellar ataxia). |  |  |
| 9 | Alteplase (tPA) & Tenecteplase (TNK) vs Tranexamic Acid (TXA) — Fibrinolytics vs Antifibrinolytic | Alteplase and tenecteplase convert plasminogen to plasmin to lyse fibrin clots in acute ischemic stroke (<4.5h), massive PE, and STEMI (contraindicated in prior hemorrhagic stroke, recent brain/spinal surgery, or active bleeding). Tranexamic acid is a synthetic lysine analog that blocks plasminogen conversion to plasmin, used in trauma hemorrhage (CRASH-2), postpartum hemorrhage, and menorrhagia. |  |  |
| 10 | Cyclophosphamide & Ifosfamide — Alkylating Mechanism, Hemorrhagic Cystitis & Mesna Prophylaxis | Nitrogen mustards activated by hepatic CYP450 to cross-link DNA at guanine N-7 positions. Hepatic metabolism produces acrolein, a urotoxic metabolite that causes hemorrhagic cystitis and bladder transitional cell carcinoma—prevented by rigorous IV hydration and Mesna (which binds and neutralizes acrolein in the bladder). |  |  |
| 11 | Montelukast — Leukotriene Receptor Antagonist Mechanism, Niche Indications & FDA Boxed Warning | Blocks CysLT1 receptors, preventing bronchoconstriction and edema caused by leukotrienes LTC4, LTD4, and LTE4. Particularly effective in aspirin-exacerbated respiratory disease (Samter triad) and exercise-induced bronchospasm. Carries an FDA Boxed Warning for serious neuropsychiatric events (agitation, depression, vivid nightmares, suicidality). |  |  |
| 12 | Pembrolizumab, Nivolumab & Ipilimumab — Immune Checkpoint Inhibitors & Immune-Related Adverse Events (irAEs) | Pembrolizumab/nivolumab block PD-1 on T cells; atezolizumab blocks PD-L1 on tumor cells; ipilimumab blocks CTLA-4 on T cells. Release the brakes on cytotoxic T-cell antitumor immunity. Cause autoimmune inflammatory toxicities (colitis, pneumonitis, thyroiditis, hypophysitis, hepatitis, myocarditis), managed by holding drug and administering systemic corticosteroids. |  |  |
| 13 | Tamoxifen vs Anastrozole/Letrozole — Endocrine Therapy Selection in ER-Positive Breast Cancer | Tamoxifen (SERM) is effective in both premenopausal and postmenopausal women (requires CYP2D6 conversion to active endoxifen; avoid strong CYP2D6 inhibitors like fluoxetine/paroxetine). Aromatase inhibitors (anastrozole, letrozole, exemestane) block peripheral conversion of androgens to estrogens and are first-line in postmenopausal women (cause arthralgias and osteoporosis). |  |  |
| 14 | Bethanechol & Pilocarpine vs Neostigmine & Pyridostigmine — Cholinergic Agonist Clinical Applications | Bethanechol (direct M3 agonist for postoperative/neurogenic urinary retention) and Pilocarpine (direct muscarinic agonist for acute glaucoma and Sjögren syndrome xerostomia). Neostigmine (reversible AChE inhibitor for postoperative ileus/Ogilvie syndrome and neuromuscular blockade reversal) and Pyridostigmine (oral AChE inhibitor first-line for Myasthenia Gravis; does not cross BBB). |  |  |
| 15 | Tiotropium + Olodaterol + Fluticasone — GOLD COPD Escalation Principle (ABE Groups) | According to GOLD guidelines, symptomatic COPD (Group B) and frequent exacerbators (Group E) are initiated on dual bronchodilator therapy (LABA + LAMA). Triple therapy (LABA + LAMA + ICS) is reserved for patients with recurrent exacerbations and blood eosinophils >= 300 cells/uL (or concomitant asthma). |  |  |
| 16 | Tamsulosin & Finasteride Combination in Benign Prostatic Hyperplasia — Dynamic vs Static Obstruction | Tamsulosin (selective alpha-1A antagonist) rapidly relaxes prostatic and bladder neck smooth muscle within days (relieves the dynamic component of BPH obstruction). Finasteride (5-alpha-reductase inhibitor) shrinks the hyperplastic glandular epithelium over 6–12 months (relieves the static component, reduces hematuria and acute urinary retention). |  |  |
| 17 | Epinephrine Auto-Injector (EpiPen) — Exact Dose, Route, Anatomic Site & Mechanism in Anaphylaxis | Intramuscular (IM) injection into the mid-anterolateral thigh (vastus lateralis): 0.3–0.5 mg of 1 mg/mL (1:1,000) solution in adults (0.3 mg via standard adult auto-injector; 0.15 mg in children 15–30 kg). Alpha-1 vasoconstriction reverses hypotension and laryngeal mucosal edema; beta-2 agonism relieves bronchospasm and stabilizes mast cells. |  |  |
| 18 | Adalimumab, Infliximab & Etanercept — TNF-Alpha Inhibitors & Mandatory Pre-Treatment Screening | Infliximab and adalimumab are monoclonal antibodies against TNF-alpha; etanercept is a decoy TNF receptor-IgG Fc fusion protein (note: infliximab/adalimumab treat Crohn disease and sarcoidosis, whereas etanercept does not). Because TNF-alpha maintains caseating granulomas, all require screening for latent Tuberculosis (IGRA/PPD) and Hepatitis B prior to initiation. |  |  |
| 19 | Cisplatin, Carboplatin & Oxaliplatin — Platinum Cross-Linking Agents & Signature Toxicities | Cross-link DNA strands to trigger apoptosis. Cisplatin causes severe nephrotoxicity (Fanconi syndrome/ATN; prevented by IV saline diuresis and amifostine) and ototoxicity. Carboplatin causes dose-limiting myelosuppression. Oxaliplatin causes cold-triggered acute dysesthesias and peripheral neuropathy. |  |  |
| 20 | Phentolamine & Phenoxybenzamine — Alpha-Adrenergic Blockers in Pheochromocytoma & Beta-Blocker Rule | Phenoxybenzamine is an irreversible non-selective alpha-1/alpha-2 blocker used preoperatively for 10–14 days before pheochromocytoma resection; phentolamine is a reversible non-selective alpha blocker used for intraoperative hypertensive crises or extravasation of norepinephrine. Alpha blockade MUST be established BEFORE giving any beta-blocker to prevent unopposed alpha-1 vasoconstriction and fatal hypertensive crisis. |  |  |
| 21 | Fluticasone & Budesonide — Inhaled Corticosteroid (ICS) Mechanism & Local Prevention Counseling | Inhibit phospholipase A2 and NF-kB transcription of inflammatory cytokines, suppressing eosinophilic airway inflammation and upregulating beta-2 receptors. Patients must rinse their mouth and spit ('rinse and spit') after every use to prevent oropharyngeal candidiasis (thrush) and dysphonia. |  |  |
| 22 | Clopidogrel, Prasugrel & Ticagrelor — P2Y12 Platelet Inhibitor Comparison | Block ADP-mediated platelet aggregation (preventing GPIIb/IIIa activation). Clopidogrel and prasugrel are thienopyridine prodrugs that irreversibly block P2Y12 (clopidogrel requires CYP2C19 activation; prasugrel is contraindicated in prior stroke/TIA). Ticagrelor is a direct, reversible P2Y12 inhibitor that does not require hepatic activation (causes benign dyspnea via adenosine reuptake inhibition). |  |  |
| 23 | Warfarin (Coumadin) — Mechanism, Initial Prothrombotic Window, INR Targets & Reversal Protocol | Inhibits vitamin K epoxide reductase (VKORC1), preventing gamma-carboxylation of Factors II, VII, IX, X, and Proteins C and S. Because Protein C and Factor VII have the shortest half-lives (~6–8h), warfarin causes a transient hypercoagulable state and skin necrosis (esp. in Protein C deficiency) unless bridged with heparin. Target INR 2.0–3.0 (2.5–3.5 for mechanical mitral valves). Reversed rapidly with 4-factor PCC + IV Vitamin K. |  |  |
| 24 | Imatinib (Gleevec), Trastuzumab (Herceptin) & Rituximab (Rituxan) — Targeted Oncology Classics | Imatinib inhibits the BCR-ABL tyrosine kinase (Philadelphia chromosome t(9;22) in CML) and c-KIT in GIST (causes fluid retention/periorbital edema). Trastuzumab is a mAb against HER2/neu (ErbB2) in breast/gastric cancer (causes reversible cardiotoxicity; check baseline ECHO). Rituximab is a chimeric anti-CD20 mAb used in B-cell non-Hodgkin lymphomas, CLL, RA, and GPA (risk of HBV reactivation and PML). |  |  |
| 25 | Doxorubicin (Adriamycin) vs Bleomycin — Anthracycline vs Glycopeptide Antitumor Antibiotics | Doxorubicin intercalates DNA, inhibits topoisomerase II, and generates iron-mediated free radicals; causes cumulative dose-dependent dilated cardiomyopathy (prevented by iron chelator dexrazoxane). Bleomycin generates free radicals that induce DNA strand breaks (used in Hodgkin lymphoma ABVD and testicular cancer); causes dose-limiting pulmonary fibrosis and flagellate hyperpigmentation (minimal myelosuppression). |  |  |
| 26 | Methotrexate — Mechanism in Malignancy vs Autoimmune Disease, Leucovorin Rescue & Organ Toxicities | Folic acid analog that competitively inhibits dihydrofolate reductase (DHFR) (and increases anti-inflammatory adenosine in RA/psoriasis). High-dose oncology regimens require leucovorin (folinic acid) rescue to protect normal bone marrow and GI mucosa. Toxicities: Hepatotoxicity/hepatic fibrosis, pulmonary fibrosis, myelosuppression, mucositis, and severe teratogenicity. |  |  |
| 27 | Norepinephrine vs Epinephrine vs Phenylephrine vs Dobutamine — Vasopressor & Inotrope Receptor Profiles | Norepinephrine (alpha-1 > beta-1; first-line vasopressor in septic/cardiogenic shock). Epinephrine (beta-1 = beta-2 > alpha-1 at low dose, alpha-1 dominant at high dose; first-line in anaphylaxis and cardiac arrest). Phenylephrine (pure alpha-1 agonist; causes reflex bradycardia). Dobutamine (beta-1 > beta-2 agonist; inodilator that increases cardiac output and decreases SVR). |  |  |
| 28 | Albuterol (SABA) vs Salmeterol/Formoterol (LABA) — Beta-2 Agonist Mechanism & GINA Asthma Monotherapy Rule | Stimulate beta-2 adrenergic receptors (Gs -> adenylyl cyclase -> increased cAMP -> bronchial smooth muscle relaxation) and drive K+ into cells (causing hypokalemia and tremor). LABAs must NEVER be used as monotherapy in asthma without an inhaled corticosteroid (ICS) due to increased asthma-related mortality; GINA guidelines recommend ICS-formoterol as preferred reliever. |  |  |
| 29 | Atropine, Glycopyrrolate & Benztropine — Antimuscarinic Clinical Differences | Atropine crosses the BBB (treats symptomatic bradycardia and organophosphate poisoning). Glycopyrrolate is a quaternary amine that does NOT cross the BBB (used parenterally with neostigmine to block peripheral muscarinic bradycardia/salivation during paralytic reversal). Benztropine crosses the BBB to treat drug-induced parkinsonism and acute dystonia. |  |  |
| 30 | Heparin-Induced Thrombocytopenia (HIT) — Pathophysiology, Timing, Paradoxical Thrombosis & Treatment | IgG antibodies form against PF4-heparin complexes (typically 5–10 days after heparin exposure), activating platelets via FcgammaRIIA receptors -> >50% platelet drop PLUS life-threatening arterial/venous thrombosis and skin necrosis. Immediately stop all heparin (and avoid warfarin initially) and start a direct thrombin inhibitor (argatroban in hepatic/renal failure or bivalirudin) or fondaparinux. |  |  |
| 31 | Vincristine & Vinblastine vs Paclitaxel & Docetaxel — Microtubule Chemotherapy Comparison | Vinca alkaloids inhibit beta-tubulin polymerization (prevent mitotic spindle assembly in M phase): Vincristine causes dose-limiting peripheral and autonomic neuropathy (paralytic ileus/foot drop), while Vinblastine 'blasts' the bone marrow. Taxanes (paclitaxel, docetaxel) hyperstabilize polymerized microtubules ('tax the mitotic spindle'), preventing disassembly (cause neuropathy and hypersensitivity). |  |  |
| 32 | Hydroxyurea — Mechanism of Action & Clinical Benefit in Sickle Cell Disease | Inhibits ribonucleotide reductase (G1/S phase arrest in myeloproliferative neoplasms) and increases fetal hemoglobin (HbF, alpha2gamma2) levels in sickle cell disease. HbF prevents polymerization of deoxygenated HbS, reducing vaso-occlusive painful crises and acute chest syndrome. |  |  |

---
Study this deck interactively with FSRS-6 spaced repetition, audio review, and multiple-choice mode at [Flashcards World](https://flashcards.world/flashcards/sets/27366501-2807-4867-a801-100d5c9b99a0/).
